Back
NEJM AI Applications
webnejm.org·nejm.org/
NEJM AI is relevant to AI safety researchers interested in real-world deployment risks, governance frameworks, and the challenges of applying AI in high-stakes domains like medicine where errors can directly harm patients.
Metadata
Importance: 45/100journal articlehomepage
Summary
The New England Journal of Medicine's AI-focused section covers clinical applications of artificial intelligence in healthcare, including diagnostic tools, predictive models, and the governance challenges of deploying AI in medical settings. It serves as a leading peer-reviewed venue for research on AI's impact on clinical practice and patient outcomes.
Key Points
- •Publishes peer-reviewed research on AI applications in clinical medicine, diagnostics, and healthcare systems
- •Addresses governance, ethics, and regulatory considerations for medical AI deployment
- •Covers risks and limitations of AI tools in high-stakes healthcare decision-making
- •Examines equity and access concerns related to AI-driven medical technologies
- •Serves as a bridge between AI technical research and clinical/policy communities
Cited by 1 page
| Page | Type | Quality |
|---|---|---|
| AI Knowledge Monopoly | Risk | 50.0 |
Cached Content Preview
HTTP 200Fetched Mar 15, 202631 KB
# homepage
## featured articles
Save
- [](https://www.nejm.org/doi/full/10.1056/NEJMoa2512911?query=featured_home)
- [Original Article](https://www.nejm.org/browse/nejm-article-type/original-article?query=featured_home)
### [Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis](https://www.nejm.org/doi/full/10.1056/NEJMoa2512911?query=featured_home)
S.D. Nathan and Others
In a phase 3 trial involving patients with idiopathic pulmonary fibrosis, inhaled treprostinil was associated with a smaller decline in forced vital capacity and a lower risk of clinical worsening than placebo over 52 weeks.
[](https://www.nejm.org/doi/full/10.1056/NEJMoa2512911?query=featured_home)
- [](https://www.nejm.org/doi/full/10.1056/NEJMoa2510703?query=featured_home)
- [Original Article](https://www.nejm.org/browse/nejm-article-type/original-article?query=featured_home)
- CME
### [Bleeding Risk with Apixaban versus Rivaroxaban](https://www.nejm.org/doi/full/10.1056/NEJMoa2510703?query=featured_home)
L.A. Castellucci and Others
In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.
[Editorial The COBRRA Trial — Ending the Venous Thromboembolism Safety Toss-up](https://www.nejm.org/doi/full/10.1056/NEJMe2600525?query=featured_home)
[](https://www.nejm.org/doi/full/10.1056/NEJMoa2510703?query=featured_home)
- [](https://www.nejm.org/do/10.1056/NEJMdo008418/full?query=featured_home)
- [Case Challenge](https://www.nejm.org/browse/nejm-media-type/case-challenge?query=featured_home)
- FREE
### [A Girl with Altered Mental Status and Hypoglycemia](https://www.nejm.org/do/10.1056/NEJMdo008418/full?query=featured_home)
A 12-year-old girl was admitted to the hospital with altered mental status and abdominal distention. The blood glucose level was 30 mg per deciliter. Symptoms abated with glucose administration. What is the diagnosis? Cast your vote. Find the answers in the full text of the case, to be published in the March 26, 2026, issue.
[Resource ID:
0fe768d9e2ad897c | Stable ID: NTlkODk3Yj